P2Y12 platelet receptors: importance in percutaneous coronary intervention

Arq Bras Cardiol. 2013 Sep;101(3):277-82. doi: 10.5935/abc.20130162. Epub 2013 Aug 6.
[Article in English, Portuguese]

Abstract

Apart from their role in hemostasis and thrombosis, platelets are involved in many other biological processes such as wound healing and angiogenesis. Percutaneous coronary intervention is a highly thrombogenic procedure inducing platelets and monocytes activation through endothelial trauma and contact activation by intravascular devices. Platelet P2Y12 receptor activation by adenosine diphosphate facilitates non-ADP agonist-mediated platelet aggregation, dense granule secretion, procoagulant activity, and the phosphorylation of several intraplatelet proteins, making it an ideal drug target. However, not all compounds that target the P2Y12 receptor have similar efficacy and safety profiles. Despite targeting the same receptor, the unique pharmacologic properties of each of these P2Y12 receptor-directed compounds can lead to very different clinical effects.

MeSH terms

  • Adenosine / analogs & derivatives
  • Adenosine / pharmacology
  • Adenosine Monophosphate / analogs & derivatives
  • Adenosine Monophosphate / pharmacology
  • Humans
  • Percutaneous Coronary Intervention*
  • Piperazines / pharmacology
  • Platelet Aggregation / drug effects*
  • Platelet Aggregation Inhibitors / pharmacology*
  • Prasugrel Hydrochloride
  • Purinergic P2Y Receptor Antagonists / pharmacology*
  • Receptors, Purinergic P2Y12 / drug effects*
  • Thienopyridines / pharmacology
  • Thiophenes / pharmacology
  • Ticagrelor

Substances

  • Piperazines
  • Platelet Aggregation Inhibitors
  • Purinergic P2Y Receptor Antagonists
  • Receptors, Purinergic P2Y12
  • Thienopyridines
  • Thiophenes
  • Adenosine Monophosphate
  • cangrelor
  • Prasugrel Hydrochloride
  • Ticagrelor
  • Adenosine